Skip to Main Content

Author Details

Andy Surinach
Genesis Research LLC
2015
36
8
Wade Schulz (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37665273Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.Future Oncol2024
37919137Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.Clin Lymphoma Myeloma Leuk2024
36934451Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.Cancer Med2023
37914825The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey.Support Care Cancer2023
37121857Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.Clin Lymphoma Myeloma Leuk2023
36947720Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography-Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study.JCO Oncol Pract2023
36971492Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.Oncologist2023
36549175Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.Gynecol Oncol2023
35031189Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.Gynecol Oncol2022
35740574Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice.Cancers (Basel)2022
35608039Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.J Med Econ2022
35621719Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.J Manag Care Spec Pharm2022
35354375Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.Curr Med Res Opin2022
36589508Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.Gynecol Oncol Rep2022
36506039Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.Gynecol Oncol Rep2022
36201207Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US.JAMA Netw Open2022
36282937Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.J Manag Care Spec Pharm2022
35285490Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.Oncologist2022
35278079Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Oncologist2022
35213741The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.Clin Pharmacol Ther2022
32778476"Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.Urol Oncol2021
34671563The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.Front Oncol2021
34402201Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019.Cancer Med2021
34811961Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.Cancer Med2021
34844493Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2.J Med Econ2021
34111762Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder.J Neurol Sci2021
34224957The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder.J Neurol Sci2021
33070660Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.Future Oncol2021
32667719Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.Cancer Med2020
32011529Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.Pancreas2020
33205069Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.Cell Rep Med2020
32997898Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.Cancer Med2020
32874209Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan.Ther Adv Med Oncol2020
31174493Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.BMC Cancer2019
28482722Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.Leuk Lymphoma2017
25785551Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.Curr Med Res Opin2015
  • 1 - 36 of 36

Recommended Authors

Michael A Golafshar
Mayo Clinic
Career Start Year 2018
Number of shared co-authors 0
Shivani Pandya
STATinMED LLC
Career Start Year 2018
Number of shared co-authors 1
Kevin A Nguyen
Veterans Affairs Palo Alto Healthcare System, Stanford University School of Medicine
Career Start Year 2017
Number of shared co-authors 0
Jessica A Lavery
Memorial Sloan Kettering Cancer Center
Career Start Year 2015
Number of shared co-authors 0
Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 0
Erqi L Pollom
Stanford University
Career Start Year 2014
Number of shared co-authors 2
Donna R Rivera
Oncology Center of Excellence
Career Start Year 2012
Number of shared co-authors 1
Irbaz Bin Riaz
Mayo Clinic
Career Start Year 2012
Number of shared co-authors 0
Marliese Alexander
Department of Pharmacy, 5Peter MacCallum Cancer Centre
Career Start Year 2011
Number of shared co-authors 0
Jeremy L Warner
Vanderbilt University Medical Center
Career Start Year 2009
Number of shared co-authors 0
Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 1
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 0
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 0
Bhumsuk Keam
Seoul National University Hospital
Career Start Year 2006
Number of shared co-authors 0
Sunita Ghosh
Cross Cancer Institute
Career Start Year 2006
Number of shared co-authors 0
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 1
Travis Osterman
Vanderbilt University Medical Center
Career Start Year 2004
Number of shared co-authors 0
Nora Horick
Massachusetts General Hospital
Career Start Year 2003
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
Toni K Choueiri
Dana-Farber Cancer Institute
Career Start Year 2002
Number of shared co-authors 1
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 1
Brian A Costello
The Mayo Clinic
Career Start Year 2001
Number of shared co-authors 0
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 0
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Deborah Schrag
Memorial-Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Craig C Earle
Odette Cancer Centre
Career Start Year 1996
Number of shared co-authors 0
Lynne Penberthy
National Cancer Institute
Career Start Year 1983
Number of shared co-authors 0

Collaborators

Carly McWilliams
Co-authored papers 1
Elodie Baumfeld Andre
Co-authored papers 1
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Co-authored papers 1
Nate Carrington
Co-authored papers 1
Chris L Pashos
Data Sciences Institute, Takeda Pharmaceuticals International Inc.
Co-authored papers 1
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Guido Steiner
Co-authored papers 1
Karim Chamie
David Geffen School of Medicine at university of california los angeles
Co-authored papers 1
Carolyn Hiller
Co-authored papers 1
Flora S Siami
HealthCore/New England Research Institutes (NERI)
Co-authored papers 1
Alejandro Zamorano
Co-authored papers 1
Wade Schulz (CM4AI)
Yale University
Co-authored papers 1
Jo Carol Hiatt
Co-authored papers 1
Aracelis Z Torres
Bloomberg School of Public Health, Johns Hopkins
Co-authored papers 1
Release 1.2